

Resource Summary Report

Generated by [kravitz2](#) on Sep 4, 2026

WinNonlin

RRID:SCR_024504

Type: Tool

Proper Citation

WinNonlin (RRID:SCR_024504)

Resource Information

URL: <https://www.certara.com/software/phoenix-pkpd/>

Proper Citation: WinNonlin (RRID:SCR_024504)

Description: Software to automate repetitive analysis steps and is widely considered the industry standard for NCA, TK, and PK/PD modeling. Used as non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling tool.

Synonyms: Phoenix WinNonlin

Resource Type: software application, software resource

Keywords: automate repetitive analysis steps, NCA, TK, PK/PD modeling, non-compartmental analysis, pharmacokinetic/pharmacodynamic, toxicokinetic, modeling tool,

Resource Name: WinNonlin

Resource ID: SCR_024504

Record Creation Time: 20231002T161336+0000

Record Last Update: 20260904T000602+0000

Ratings and Alerts

No rating or validation information has been found for WinNonlin.

No alerts have been found for WinNonlin.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2013 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. *Molecular cancer therapeutics*, 25(7), 1157.

Koyama T, et al. (2026) A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. *Investigational new drugs*.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Wei X, et al. (2026) Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. *Cancer discovery*, 16(6), 1152.

Grafals-Ruiz N, et al. (2026) M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer. *Molecular cancer therapeutics*.

Otani Y, et al. (2026) One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants. *Advances in therapy*, 43(1), 377.

Hoch M, et al. (2026) Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants. *Clinical pharmacology in drug development*, 15(2), e1611.

Zhang CX, et al. (2026) Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis. *Clinical and translational science*, 19(1), e70453.

Gareau A, et al. (2026) Serum Symmetric Dimethylarginine as a Predictor of Toxicity of Carboplatin in Dogs. *Veterinary and comparative oncology*, 24(1), 140.

Fabbrini E, et al. (2026) Sustained Action of Imapexptide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers. *The Journal of clinical endocrinology and metabolism*, 111(6), 1628.

Op 't Hoog CJP, et al. (2026) Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. *British journal of clinical pharmacology*, 92(4), 1117.

Jacobs ME, et al. (2026) Metformin in the Horse: Pharmacokinetics and Detection Times Using Monte Carlo Simulations. *Drug testing and analysis*, 18(1), 139.

Youssef AS, et al. (2026) A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when

Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants. *Clinical pharmacology in drug development*, 15(2), e1615.

Seefried L, et al. (2026) A randomized Phase 1b trial evaluating the pharmacodynamics of ilofotase alfa in adults with hypophosphatasia. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 41(3), 231.

Kemmer C, et al. (2026) Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers. *Antimicrobial agents and chemotherapy*, 70(4), e0158225.

Iavarone L, et al. (2026) Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent. *Journal of clinical pharmacology*, 66(3), e70161.

Zhu J, et al. (2026) Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open-Label, Fixed Sequence, Phase 1 Study. *Clinical and translational science*, 19(4), e70481.

Kancharla P, et al. (2026) Potent acridone antimalarial against all three life stages of Plasmodium. *Nature communications*, 17(1).

Kumar S, et al. (2026) Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions. *Clinical pharmacology in drug development*, 15(4), e70053.

Gui Z, et al. (2026) Solamargin-functionalized gold nanoparticles codelivering photothermal-immunotherapy for triple-negative breast cancer. *Breast cancer (Tokyo, Japan)*, 33(3), 705.